Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome

Arthritis Care and Research

Volumn 64, Issue 10, 2012, Pages 1576-1583

  Rodrigues, Carlos Ewerton Maia ^a   Bonfá, Eloisa ^a   Caleiro, Maria Teresa Correia ^a   Vendramini, Margarete B ^a   Bueno, Cleonice ^a   Lopes, Jaqueline B ^a   De Carvalho, Jozélio Freire ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; C REACTIVE PROTEIN; CHLOROQUINE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; THYROTROPIN; URIC ACID;

ADULT; ANGINA PECTORIS; ANTIPHOSPHOLIPID SYNDROME; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FREE THYROXINE INDEX; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; MULTIVARIATE ANALYSIS; PREVALENCE; PROTEIN BLOOD LEVEL;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERIES; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 84869151795     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21701     Document Type: Article

References (45)

1. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.
2. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666-73. (Pubitemid 41099045)
3. Pereira RM, de Carvalho JF, Bonfa E. Metabolic syndrome in rheumatological diseases. Autoimmun Rev 2009; 8: 415-9.
4. Medina G, Gutierrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev 2011; 10: 214-7.
5. De Groot PG, Derksen RH, de Laat B. Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. Semin Thromb Hemost 2008; 34: 347-55.
6. Schalkwijk CG, Stehouwer CD. PAI-1 inhibition in obesity and the metabolic syndrome: a promising therapeutic strategy [editorial]. Thromb Haemost 2006; 96: 698-9. (Pubitemid 44883807)
7. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.
8. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978-86. (Pubitemid 38544279)
9. Koh SB, Park JK, Yoon JH, Chang SJ, Oh SS, Kim JY, et al. Preliminary report: a serious link between adiponectin levels and metabolic syndrome in a Korean nondiabetic population. Metabolism 2010; 59: 333-7.
10. Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
11. National Cholesterol Education Program. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
12. Kones R. Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag 2010; 9: 635-56.
13. Bernstein MS, Morabia A, Sloutskis D. Definition and prevalence of sedentarism in an urban population. Am J Public Health 1999; 89: 862-7. (Pubitemid 29282705)
14. Haris EN, Pierangeli S, Birch D. Cardiolipin wet workshop report. Am J Clin Path 1994; 101: 616-24.
15. Louisville IgG and IgM anti-cardiolipin calibrator data sheet (LAPL-GM-200). 2001. http://www.inovadx.com/PDF/di/ MK071-IT.pdf.
16. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-80. (Pubitemid 13106884)
17. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-80. (Pubitemid 12034053)
18. Warnick GR, Cheung NC, Albers JJ. Comparison of current methods for high density lipoprotein cholesterol quantification. Clin Chem 1979; 25: 596-604. (Pubitemid 9166999)
19. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
21. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004; 110: 803-9. (Pubitemid 39096007)
22. Danowski A, de Azevedo MN, Papi AS. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36: 1195-9.
23. Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15: 562-9. (Pubitemid 44661742)
24. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108: 1546-51. (Pubitemid 37187778)
25. Lopez-Pedrera C, Cuadrado MJ, Hernandez V, Buendia P, Aguirre MA, Barbarroja N, et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum 2008; 58: 2835-44.
26. Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, Grossi C, et al. Patients with antiphospholipid syndrome display endothelial pertubation. J Autoimmun 2010; 34: 105-10.
27. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109: 422-30. (Pubitemid 46105935)
28. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236-50.
29. Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, Kveder T. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res 2006; 118: 455-61. (Pubitemid 44308637)
30. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, deGroot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8: 998-1005.
31. Ruffatti A, del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70: 1083-6.
32. Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM, et al. Anti-2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 2007; 5: 2421-8.
33. Ruffati A, del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70: 1083-6.
34. Telles R, Lanna C, Ferreira G, Ribeiro A. Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus 2010; 19: 803-9.
35. Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, Barbarroja N, Perez-Sanchez C, Buendia P, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011; 70: 675-82.
36. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47. (Pubitemid 28213628)
37. Jara IJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003; 25: 79-88.
38. Sacre K, Brihaye B, Hyafil F, Serfaty JM, Escoubet B, Zennaro MC, et al. Asymptomatic myocardial ischemic disease in anti-phospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum 2010; 62: 2093-100.
39. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, Berger RD. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7. (Pubitemid 32977500)
40. Kaplan SD, Chatash EK, Pizzarello RA, Furie RA. Cardiac manifestations of the antiphospholipid syndrome. Am Heart J 1992; 124: 1331-8.
41. Puisieux F, de Groote P, Masy E, Di Pompeo C, Millaire A, Bouillanne O, et al. Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease. Am J Med 2000; 109: 635-41.
42. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47. (Pubitemid 43739380)
43. Long BR, Leya F. The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin N Am 2008; 22: 79-94.
44. Andreoli L, Tincani A. Beyond the 'syndrome': antiphospholipid antibodies as risk factors. Arthritis Rheum 2012; 64: 342-5.
45. De Souza AW, Silva NP, de Carvalho JF, D'Almeida V, Noguti MA, Sato EI. Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus 2007; 16: 782-7. (Pubitemid 350069790)